GlassScriptPhysician profile
Karis Martinez
NPI 1659627701
$2,142.55
in general payments reported to CMS, 2019-2025
12 companies · $64.02 in 2025
The $64.02 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $973 · 2023: $438 · 2024: $381 · 2025: $64.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $543.78 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $338.51 | 2022-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $224.39 | 2021-2022 | |
| Ucb, INC. | $174.47 | 2023-2024 | Nayzilam, Briviact |
| Abbvie INC. | $165.18 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $125.05 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $121.16 | 2024 | Rexulti |
| Philips North America LLC | $114.30 | 2022 | |
| Dexcom, INC. | $108.32 | 2023 | Dexcom G7 Gss (161) |
| Lilly USA, LLC | $83.52 | 2022 | |
| Melinta Therapeutics, LLC | $79.85 | 2022-2023 | Kimyrsa |
| Integra Lifesciences Corporation | $64.02 | 2025 | Codman Hakim, Cusa Clarity, Codman Certas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karis Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.